Receipt and duration of buprenorphine treatment during pregnancy and postpartum periods in a national privately-insured cohort

Wang, Xi; Meisel, Zachary; Kellom, Katherine; Whitaker, Jennifer; Strane, Douglas; Chatterjee, Anyun; Rosenquist, Rebecka; Matone, Meredith

doi:10.1016/j.dadr.2023.100206

Cited by 1 publication

(1 citation statement)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unfortunately, reported postpartum MOUD discontinuation rates are high, between 36% [4] and 65% [5]. In one study of over 1500 birthing people diagnosed with OUD, 42.9% received buprenorphine treatment throughout their pregnancy; however, one third experienced a treatment disruption during the postpartum period [6]. Additional research is needed to identify factors that may be driving high rates of postpartum discontinuation of medication for OUD in order to develop effective strategies to increase consistent medication continuation during this vulnerable period.…”

Section: Introductionmentioning

confidence: 99%

Association of Receipt of Opioid Prescription for Acute Post-Delivery Pain Management with Buprenorphine Discontinuation among Postpartum People with Opioid Use Disorder

Hallet,

Zhu,

Shadowen

et al. 2024

Pharmacoepidemiology

View full text Add to dashboard Cite

Buprenorphine is a safe and effective medication to treat opioid use disorder (OUD) in pregnant patients and is intended to be continued throughout pregnancy, delivery, and at least the one-year postpartum period. However, delivery often involves the need for acute pain management with opioid medications, such as after a cesarean section. For patients receiving buprenorphine, the provision of prescription opioids may negatively impact OUD treatment outcomes; however, not optimally managing acute pain may also impede OUD treatment benefit. Evidence is needed to disentangle the impacts of opioid prescription provision and methods of pain management in the immediate postpartum period on OUD treatment trajectories, ultimately to inform clinical guidelines tailored to the unique needs of pregnant and postpartum people receiving buprenorphine. Accordingly, this study took an initial step towards this goal to conduct a secondary analysis of a retrospective cohort of pregnant patients taking buprenorphine for OUD at the time of delivery (n = 142) to determine whether receipt of an opioid prescription at birth hospitalization discharge was associated with the time of buprenorphine discontinuation within the 12 months following delivery. Among the sample, 26% (n = 37) were prescribed an opioid at the time of birth hospitalization discharge. The number of weeks post-delivery until buprenorphine discontinuation occurred was shorter amongst patients who were prescribed an opioid (median 11 weeks) compared to patients who were not prescribed an opioid (median 39 weeks; p < 0.001 by Mann–Whitney U test). However, a Cox regression model reported that receipt of an opioid prescription following delivery did not significantly increase the hazard ratio for buprenorphine discontinuation. In other words, OUD patients not prescribed an opioid at birth hospitalization discharge continued their buprenorphine for a longer median duration after delivery compared to their counterparts who received prescription opioids; yet, this finding did not reach statistical significance when taking into account additional clinical variables. The findings indicate how further research is warranted to inform evidence-based post-delivery pain practices for postpartum OUD treatment patients.

show abstract

Section: Introductionmentioning

confidence: 99%